Date: 2017-06-29
Type of information: Nomination
Compound:
Company: ITeos Therapeutics (Belgium)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On June 29, 2017, iTeos Therapeutics announced that Dr. Mohamed Ragab, M.D., has been appointed as Vice President of Corporate Development. He will be responsible for overseeing global strategic business opportunities that support the growth of iTeos both clinically and operationally. Dr. Ragab was most recently the Vice President, Search and Evaluation, Oncology at BMS where he was involved in many major immune-oncology deals. Prior to that, he was Global Partnering Head, Oncology at Hoffman-La Roche (part of Roche Group) and before that he was the Life Cycle Leader, Anemia Oncology. He also held various positions at Pfizer, Ortho Biotech and Schering-Plough (now Merck & Co.). He holds a Master Degree in Radiation Oncology from Cairo University School of Medicine and holds a Bachelor of Medicine and Surgery from Cairo University School of Medicine.
Financial terms:
Latest news:
Is general: Yes
